品牌现货直购
供应商:我要出现这里








查看所有供应商和价格请点击:

70458-96-7生产厂家

70458-96-7价格

70458-96-7

70458-96-7结构式
70458-96-7结构式

化源商城直购

中文名 氟哌酸
英文名 norfloxacin
中文别名 1-乙基-6-氟-1,4-二氢-4-氧代-7-(1-哌嗪基)-3-喹啉羧酸
诺氟沙星
英文别名 Zomxin
1-Ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid
Fulgram
Barazan
NORFLOXACINE
CHIBROXIN
Noflo
Utinor
EINECS 274-614-4
Nolicin
Sebercim
Chibroxol
Zoroxin
4803P
3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-
am-715
MFCD08060466
1-ethyl-6-fluoro-4-oxo-7-piperazinyl-1,4-dihydro-quinoline-3-carboxylic acid
Norfloxacin
1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid
Floxacin
1-ethyl-6-fluoro-7-piperazino-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
Noroxin
Lexinor
1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
密度 1.3±0.1 g/cm3
沸点 555.8±50.0 °C at 760 mmHg
熔点 220°C
分子式 C16H18FN3O3
分子量 319.331
闪点 289.9±30.1 °C
精确质量 319.133209
PSA 74.57000
LogP 0.82
外观性状 灰白色至淡黄色结晶粉末
蒸汽压 0.0±1.6 mmHg at 25°C
折射率 1.595
储存条件

存放在密封容器内,并放在阴凉,干燥处,2-8 ºC保存。

稳定性

常温常压下稳定,远离氧化剂。

分子结构

1、 摩尔折射率:80.70

2、 摩尔体积(cm3/mol):237.4

3、 等张比容(90.2K):641.2

4、 表面张力(dyne/cm):53.1

5、 极化率(10-24cm3):31.99

计算化学

1.疏水参数计算参考值(XlogP):无

2.氢键供体数量:2

3.氢键受体数量:7

4.可旋转化学键数量:3

5.互变异构体数量:无

6.拓扑分子极性表面积72.9

7.重原子数量:23

8.表面电荷:0

9.复杂度:519

10.同位素原子数量:0

11.确定原子立构中心数量:0

12.不确定原子立构中心数量:0

13.确定化学键立构中心数量:0

14.不确定化学键立构中心数量:0

15.共价键单元数量:1

更多

1. 性状:类白色至淡黄色结晶性粉末。无臭,味微苦。

2. 密度(g/mL,25/4℃):未确定

3. 相对蒸汽密度(g/mL,空气=1):未确定

4. 熔点(ºC):227-228

5. 沸点(ºC,常压):556

6. 沸点(ºC,5.2kPa):未确定

7. 折射率:未确定

8. 闪点(ºC):290

9. 比旋光度(º):未确定

10. 自燃点或引燃温度(ºC):未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性:易溶于水,水中溶解度为10%(g/ml,25℃),极微溶于乙醇,几乎不溶于甲醇,氯仿。


Section I.Chemical Product and Company Identification
Chemical Name Norfloxacin
Portland OR
Synonym3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-
dihydro-4-oxo-7-(1-piperazinyl)- (CA INDEX NAME);
1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-
3-quinolinecarboxylic Acid
Chemical FormulaC16H18FN3O3
CAS Number70458-96-7

Section II.Composition and Information on Ingredients
Toxicology Data
Chemical NameCAS Number Percent (%)TLV/PEL
Min. 98.0 Not available.Rat LD50 (oral) >4 gm/kg
Norfloxacin70458-96-7
(HPLC,T)Mouse LD50 (intraperitoneal) 1064
mg/kg
Rat LD50 (intravenous) 245 mg/kg

Section III. Hazards Identification
No specific information is available in our data base regarding the toxic effects of this material for humans. However,
Acute Health Effects
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling
this compound.
CARCINOGENIC EFFECTS : Not available.
Chronic Health Effects
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Reproductive effects.
Rat TDLo Oral 1375 mg/kg, female 7-17 days of pregnancy
Toxic Effects:
Specific Developmental Abnormalities - Musculoskeletal system
Effects on Newborn - Behavioral
Rabbit Oral 1300 mg/kg, female 6-18 days of pregnancy
Toxic Effects:
Effects on Fertility - Litter size
Effects on Embryo or Fetus - Fetotoxicity
Effects on Embryo or Fetus - Fetal death
Rabbit Oral 1625 mg/kg, female 13 days prior to mating
Toxic Effects:
Maternal Effects - Ovaries, fallopian tubes
Maternal Effects - Uterus, cervix, vagina
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.

Section IV.First Aid Measures
Eye ContactCheck for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at least 15
minutes. Get medical attention.
Skin ContactIn case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes. Wash clothing
before reuse. Thoroughly clean shoes before reuse. Get medical attention.
InhalationIf the victim is not breathing, perform mouth-to-mouth resuscitation. Loosen tight clothing such as a collar, tie, belt or
waistband. If breathing is difficult, oxygen can be administered. Seek medical attention if respiration problems do not
improve.
INDUCE VOMITING by sticking finger in throat. Lower the head so that the vomit will not reenter the mouth and throat.
Ingestion
Loosen tight clothing such as a collar, tie, belt or waistband. If the victim is not breathing, perform mouth-to-mouth
resuscitation. Examine the lips and mouth to ascertain whether the tissues are damaged, a possible indication that the toxic
material was ingested; the absence of such signs, however, is not conclusive.
Continued on Next Page
Norfloxacin

Section V.Fire and Explosion Data
Not available.
FlammabilityMay be combustible at high temperature.Auto-Ignition
Flammable LimitsNot available.
Flash PointsNot available.
Combustion ProductsThese products are toxic carbon oxides (CO, CO2), nitrogen oxides (NO, NO2), halogenated compounds.
WARNING: Highly toxic HF gas is produced during combustion.
Fire HazardsNot available.
Risks of explosion of the product in presence of mechanical impact: Not available.
Explosion Hazards
Risks of explosion of the product in presence of static discharge: Not available.
Fire Fighting Media
SMALL FIRE: Use DRY chemical powder.
LARGE FIRE: Use water spray, fog or foam. DO NOT use water jet.
and Instructions
Consult with local fire authorities before attempting large scale fire-fighting operations.

Section VI.Accidental Release Measures
Spill CleanupHygroscopic material.
Use a shovel to put the material into a convenient waste disposal container. Finish cleaning the spill by rinsing any
Instructions
contaminated surfaces with copious amounts of water. Consult federal, state, and/or local authorities for assistance on
disposal.

Section VII. Handling and Storage
HYGROSCOPIC. Keep away from heat. Mechanical exhaust required. When not in use, tightly seal the container and store
Handling and Storage
in a dry, cool place. Avoid excessive heat and light. Do not breathe dust.
Information
Always store away from incompatible compounds such as oxidizing agents, moisture.

Section VIII. Exposure Controls/Personal Protection
Engineering ControlsUse process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below recommended
exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to airborne contaminants
below the exposure limit.
Personal ProtectionSplash goggles. Lab coat. Dust respirator. Boots. Gloves. Suggested protective clothing might not be sufficient; consult a
specialist BEFORE handling this product. Be sure to use a MSHA/NIOSH approved respirator or equivalent.
Not available.
Exposure Limits

Section IX. Physical and Chemical Properties
Physical state @ 20°CSolid. (Very pale yellow ~ pale yellow,SolubilitySolubility at 25°C (mg/ml): water 0.28;
crystal ~ powder.)
methanol 0.98; ethanol 1.9; acetone 5.1;
chloroform 5.5; diethyl ether 0.1; benzene
Not available.
Specific Gravity
0.15; ethyl acetate 0.94; octyl alcohol 5.1;
glacial acetic acid 340.
Solubility in water is pH dependent,
increasing sharply at pH <5 or at pH >10.
Molecular Weight319.33Partition CoefficientLOG Pow: 0.46
Boiling PointNot available.Not applicable.
Vapor Pressure
Melting Point221°C (429.8°F)Vapor DensityNot available.
Not available.Not available.
Refractive IndexVolatility
Critical TemperatureNot available.OdorNot available.
Not available.Not available.
ViscosityTaste

Section X.Stability and Reactivity Data

This material is stable if stored under proper conditions. (See Section VII for instructions)
Stability
Conditions of InstabilityAvoid excessive heat and light. Hygroscopic; keep container tightly closed.
IncompatibilitiesReactive with oxidizing agents, moisture.
Continued on Next Page
Norfloxacin

Section XI. Toxicological Information
RTECS NumberVB2005000
Eye Contact. Ingestion. Inhalation.
Routes of Exposure
Toxicity DataRat LD50 (oral) >4 gm/kg
Mouse LD50 (intraperitoneal) 1064 mg/kg
Rat LD50 (intravenous) 245 mg/kg
Chronic Toxic EffectsCARCINOGENIC EFFECTS : Not available.
MUTAGENIC EFFECTS : Not available.
TERATOGENIC EFFECTS : Not available.
DEVELOPMENTAL TOXICITY: Reproductive effects.
Rat TDLo Oral 1375 mg/kg, female 7-17 days of pregnancy
Toxic Effects:
Specific Developmental Abnormalities - Musculoskeletal system
Effects on Newborn - Behavioral
Rabbit Oral 1300 mg/kg, female 6-18 days of pregnancy
Toxic Effects:
Effects on Fertility - Litter size
Effects on Embryo or Fetus - Fetotoxicity
Effects on Embryo or Fetus - Fetal death
Rabbit Oral 1625 mg/kg, female 13 days prior to mating
Toxic Effects:
Maternal Effects - Ovaries, fallopian tubes
Maternal Effects - Uterus, cervix, vagina
Repeated or prolonged exposure to this compound is not known to aggravate existing medical conditions.
Acute Toxic EffectsNo specific information is available in our data base regarding the toxic effects of this material for humans. However,
exposure to any chemical should be kept to a minimum. Skin and eye contact may result in irritation. May be harmful if
inhaled or ingested. Always follow safe industrial hygiene practices and wear proper protective equipment when handling this
compound.

Section XII.Ecological Information
Not available.
Ecotoxicity
Not available.
Environmental Fate

Section XIII. Disposal Considerations
Waste DisposalRecycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system. Observe all
federal, state and local regulations when disposing of the substance.

Section XIV. Transport Information
DOT ClassificationNot a DOT controlled material (United States).
PIN NumberNot applicable.
Proper Shipping NameNot applicable.
Packing Group (PG)Not applicable.
DOT Pictograms

Section XV. Other Regulatory Information and Pictograms
TSCA Chemical InventoryThis product is NOT on the EPA Toxic Substances Control Act (TSCA) inventory. The following notices are required by 40
CFR 720.36 (C) for those products not on the inventory list:
(EPA)
(i) These products are supplied solely for use in research and development by or under the supervision of a technically
qualified individual as defined in 40 CFR 720.0 et sec.
(ii) The health risks of these products have not been fully determined. Any information that is or becomes available will be
supplied on an MSDS sheet.
WHMIS ClassificationOn DSL.
(Canada)
EINECS Number (EEC) 274-614-4
EEC Risk StatementsNot available.
Japanese Regulatory Data Not available.
Continued on Next Page


SECTION 16 - ADDITIONAL INFORMATION
N/A

毒理学数据:

小鼠,大鼠LD50(mg/kg):全部>4000经口;全部1500皮下注射;470,>500肌内注射;220,270静脉注射。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
VB2005000
CHEMICAL NAME :
3-Quinolinecarboxylic acid, 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-
CAS REGISTRY NUMBER :
70458-96-7
BEILSTEIN REFERENCE NO. :
0567897
LAST UPDATED :
199612
DATA ITEMS CITED :
33
MOLECULAR FORMULA :
C16-H18-F-N3-O3
MOLECULAR WEIGHT :
319.37
WISWESSER LINE NOTATION :
T66 BN EVJ B2 DVQ HF I- DT6M DNTJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
94 mg/kg/13D-I
TOXIC EFFECTS :
Musculoskeletal - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
48 mg/kg/2D-I
TOXIC EFFECTS :
Liver - hepatitis (hepatocellular necrosis), zonal Behavioral - muscle weakness Musculoskeletal - joints
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>4 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>1500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
245 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>500 mg/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - other changes
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
4 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1064 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>1500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
220 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
470 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - species unspecified
DOSE/DURATION :
>4 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1400 mg/kg/2W-I
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - retinal changes (pigmentary depositions, retinitis, other)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
9 gm/kg/30D-I
TOXIC EFFECTS :
Musculoskeletal - joints
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1375 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2750 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
20 gm/kg
SEX/DURATION :
male 61 day(s) pre-mating female 15 day(s) pre-mating - 6 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 gm/kg
SEX/DURATION :
male 61 day(s) pre-mating female 15 day(s) pre-mating - 6 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1250 mg/kg
SEX/DURATION :
female 6-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2 gm/kg
SEX/DURATION :
female 10-20 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - other effects Endocrine - estrogenic Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
4650 mg/kg
SEX/DURATION :
female 20-50 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1625 mg/kg
SEX/DURATION :
female 13 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1300 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1300 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1300 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
Micronucleus test

MUTATION DATA

TYPE OF TEST :
Unscheduled DNA synthesis
TEST SYSTEM :
Rodent - rat Liver
DOSE/DURATION :
310 umol/L
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 221,263,1989

个人防护装备 Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
危害码 (欧洲) Xn: Harmful;
风险声明 (欧洲) R20/21/22
安全声明 (欧洲) 26-37/39
危险品运输编码 NONH for all modes of transport
WGK德国 2
RTECS号 VB2005000
海关编码 2933990090

邻二氯苯经硝化,或对硝基氯苯经氯化均可得3,4-二氯硝基苯。再在二甲亚砜中,和氟化钾回流,氟化得3-氯-4-氟硝基苯。在盐酸或乙酸水溶液存在下,用铁粉还原成3-氯-4-氟苯胺。接着和原甲酸三乙酯及丙二酸二乙酯(生成乙氧基亚甲基丙二酸二乙酯)在硝酸铵存在下回流,得缩合产物。在液体石蜡或二苯醚中加热环合,生成7-氯-6-氟-4-羟基喹啉-3-羧酸乙酯。进行乙基化后,再水解得乙基化产物。最后与哌嗪缩合得诺氟沙星。其工艺比较成熟,收率较高,一般能达到40%~65%,但7位引入哌嗪基时,6位氟原子被取代的副产物可占25%,分离困难,影响收率。以对硝基氯苯计总收率为8%以上。

70458-96-7 preparation
在引入吡嗪环前,1-乙基-6-氟-7-氯-1,4-二氢-4-氧代喹啉-8-羧酸乙酯先和氟硼酸或三氟化硼-乙醚或乙酸硼反应,使4位上的羰基形成硼螯合物,然后再引入吡嗪基,可使7位氟被置换的副反应减少,收率可提高15%以上,且产品的质量改善。

70458-96-7 preparation
诺氟沙星的合成,国内外研究较多,但真正用于工业生产的却不多。其合成路线的改进主要体现在两个方面。一是对成环工艺进行改进,二是在哌嗪基的引入上做些文章。

海关编码 2933990090
中文概述 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%